Search
Search Results
-
Treatment of HER2-positive cutaneous apocrine carcinoma of the axilla
Cutaneous apocrine carcinoma (CAC) is an extremely rare skin appendage malignant tumor that develops in the apocrine sweat glands, and no...
-
HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study
BackgroundHER2-positive (HER2 +) invasive lobular breast cancer (ILC) is rare and poorly characterised. In particular, patient outcomes compared to...
-
High-grade HER2-positive mucoepidermoid carcinoma of the breast: a case report and review of the literature
BackgroundMucoepidermoid carcinoma of the breast is a rare special type of salivary gland-like tumor of the breast, usually displaying...
-
Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis
PurposeDuctal carcinoma in situ (DCIS) is present in more than half of HER2-positive invasive breast cancer (IBC). Recent studies show that DCIS...
-
Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation
BackgroundAggressive invasion, high recurrence rate, and poor prognosis are common features of the human epidermal growth factor receptor-2...
-
Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) has been the most challenging subtype of BC, consisting of 20% of BC with...
-
Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer
ObjectivesThe aim of this study is to investigate the added value of diffusion-weighted imaging (DWI) to dynamic-contrast enhanced (DCE)-MRI to...
-
Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients
Different targeted therapy options exist for treating HER2-positive metastatic breast cancer patients. This study evaluated the efficacy and...
-
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy
BackgroundEndocrine resistant metastatic disease develops in ~ 20–25% of hormone-receptor-positive (HR+) breast cancer (BC) patients despite...
-
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
Purpose of reviewTo summarize the treatment strategies for patients with human epidermal growth factor receptor 2 (HER2)-positive disease and...
-
Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
BackgroundWith advances in breast cancer treatment, the importance of de-escalation therapy to reduce harm during the treatment of elderly patients...
-
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines
Small molecule Bruton’s tyrosine kinase (BTK) inhibitors have been developed for the treatment of various haemato-oncological diseases, and ibrutinib...
-
The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer
PurposeAchieving a pathological complete response (pCR) after neoadjuvant therapy in HER2-positive breast cancer patients is the most significant...
-
Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
PurposeTo study the clinicopathological variables connected with disease-free survival (DFS) as well as overall survival (OS) in patients who are...
-
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
BackgroundThis prospective study aims to investigate the efficacy and safety of pyrotinib (P) combined with 4 cycles of epirubicin and...
-
Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
PurposePoziotinib is an irreversible pan-inhibitor of the human epidermal growth factor receptor (HER) that has shown acceptable tolerability and...
-
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
PurposeMammography screening has increased the detection of subcentimeter breast cancers. The prognosis for estrogen receptor (ER)-positive and human...
-
Correlation between androgen receptor expression and pathological response rate in pre-operative HER2-positive breast cancer patients
PurposeIn this study, we aimed to explore the potential significance of AR expression in HER2-positive breast cancer patients who underwent...
-
Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study
BackgroundThe objective of this study was to develop a model combining ultrasound (US) and clinicopathological characteristics to predict the...
-
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2...
